{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:14:26Z","timestamp":1778753666793,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07004-1","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:34:22Z","timestamp":1777264462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential impact of allogeneic stem-cell transplantation on large B-cell lymphomas and peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"105","author":[{"given":"Futoshi","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"9","key":"7004_CR1","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/cancers13092075","volume":"13","author":"B Burkhardt","year":"2021","unstructured":"Burkhardt B et al (2021) Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers 13(9):2075","journal-title":"Cancers"},{"issue":"1","key":"7004_CR2","doi-asserted-by":"publisher","first-page":"17496","DOI":"10.1038\/s41598-023-44241-0","volume":"13","author":"G-J Min","year":"2023","unstructured":"Min G-J et al (2023) The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed\/refractory diffuse large B cell lymphoma. Sci Rep 13(1):17496","journal-title":"Sci Rep"},{"key":"7004_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li L-R, Young KH (2020) New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 13:175","journal-title":"J Hematol Oncol"},{"issue":"20","key":"7004_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"key":"7004_CR5","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"N-HSLC Project","year":"1997","unstructured":"(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood J Am Soc Hematol 89(11):3909\u20133918","journal-title":"Blood"},{"key":"7004_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","volume":"83","author":"JM Andr\u00e9s","year":"2012","unstructured":"Andr\u00e9s JM (2012) Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol\/Hematol 83:293\u2013302","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"7004_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl 15:367\u2013369","journal-title":"Biol Blood Marrow Transpl"},{"key":"7004_CR8","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15:1628\u20131633","journal-title":"Biol Blood Marrow Transpl"},{"key":"7004_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"7004_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"7004_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21:389\u2013401","journal-title":"Biol Blood Marrow Transplant"},{"key":"7004_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software EZRfor medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"7004_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.14046","volume":"174","author":"TS Fenske","year":"2016","unstructured":"Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT et al (2016) Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 174:235\u2013248","journal-title":"Br J Haematol"},{"key":"7004_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41409-021-01264-3","volume":"56","author":"L Bento","year":"2021","unstructured":"Bento L, Guti\u00e9rrez A, Novelli S, Montoro J, Pi\u00f1ana JL, L\u00f3pez-Corral L et al (2021) Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: Spanish multicenter GETH\/GELTAMO study. Bone Marrow Transpl 56:1919\u20131928","journal-title":"Bone Marrow Transpl"},{"key":"7004_CR15","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00277-019-03835-3","volume":"98","author":"K Izumi","year":"2019","unstructured":"Izumi K, Kanda J, Nishikori M, Arai Y, Ishikawa T, Yoshioka S et al (2019) Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. Ann Hematol 98:2815\u20132823","journal-title":"Ann Hematol"},{"key":"7004_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","volume":"132","author":"N Schmitz","year":"2018","unstructured":"Schmitz N, Lenz G, Stelljes M (2018) Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood 132:245\u2013253","journal-title":"Blood"},{"key":"7004_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41409-018-0360-9","volume":"54","author":"G Wulf","year":"2019","unstructured":"Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M et al (2019) Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transpl 54:877\u2013884","journal-title":"Bone Marrow Transpl"},{"key":"7004_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","volume":"132","author":"D Sano","year":"2018","unstructured":"Sano D, Nastoupil LJ, Fowler NH, Fayad L, Hagemeister FB, Lee HJ et al (2018) Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma. Blood 132:96\u201396","journal-title":"Blood"},{"key":"7004_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356","journal-title":"N Engl J Med"},{"key":"7004_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J et al (2024) Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143:404\u2013416","journal-title":"Blood"},{"key":"7004_CR21","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-220525","volume":"114","author":"MR Verneris","year":"2009","unstructured":"Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al (2009) Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 114:4293\u20134299","journal-title":"Blood"},{"key":"7004_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D et al (2016) Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127:1044\u20131051","journal-title":"Blood"},{"key":"7004_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1470-2045(10)70127-3","volume":"11","author":"M Eapen","year":"2010","unstructured":"Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W et al (2010) Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11:653\u2013660","journal-title":"Lancet Oncol"},{"key":"7004_CR24","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/leu.2014.145","volume":"28","author":"M Stern","year":"2014","unstructured":"Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M et al (2014) Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 28:2235\u20132240","journal-title":"Leukemia"},{"key":"7004_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/bjh.19041","volume":"203","author":"M Watanabe","year":"2023","unstructured":"Watanabe M, Kanda J, Fukuda T, Uchida N, Ikegame K, Kataoka K et al (2023) Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy. Br J Haematol 203:446\u2013459","journal-title":"Br J Haematol"},{"key":"7004_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/10428194.2024.2438805","volume":"66","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Levien L, Mazzeo P, Jung W, Leha A, Koch R et al (2025) Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning. Leuk Lymphoma 66:668\u2013679","journal-title":"Leuk Lymphoma"},{"key":"7004_CR27","doi-asserted-by":"publisher","first-page":"e2104504118","DOI":"10.1073\/pnas.2104504118","volume":"118","author":"M Fangazio","year":"2021","unstructured":"Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J et al (2021) Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 118:e2104504118","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07004-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:28Z","timestamp":1778750548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07004-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7004"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07004-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The requirement for informed consent was waived because of the retrospective nature of the study. The study was approved by the Institutional Review Board of Toranomon Hospital (approval no. 2499).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}